Phase 2 Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 80 years, of any gender
- People whose doctors have determined that coronary artery bypass graft (CABG) heart surgery is an appropriate treatment for long-term reduced blood flow to the heart
- People whose heart pumping strength (measured by echocardiogram or cardiac MRI) is at or below 40%
- People whose heart failure symptoms fall within a moderate-to-severe range on a standard medical scale (New York Heart Association grade II–IV)
- People, or their legal guardians, who have agreed to take part and have signed a consent form
Who may not be able to join:
- People whose heart pumping strength is at or below 20% (as measured during the screening period)
- People whose reduced heart function is not caused by reduced blood flow to the heart — for example, those with sudden-onset heart failure, an enlarged/weakened heart muscle from non-blood-flow causes, severe right-sided heart failure, or severely high blood pressure in the lungs
- People who need additional heart surgical procedures performed at the same time as the bypass surgery — including, but not limited to, valve repair, heart defect correction, or removal of blood clots or growths in the heart
- People who had a serious heart attack (with specific ECG changes) or a stroke within the month before enrolling
- People with dangerous, uncontrolled irregular heart rhythms
- People who have already had, or are on a waiting list for, a heart transplant or a surgically implanted heart-assist device
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 86+13701695256
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
In phase I, primary outcome will be measured with safety events including DLT, AE, SAE, TEAE, and MACE. In phase II, primary outcome will be measured with the change in LVEF based on CMR detection after 6 months of administration.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.